Adriamycin. A new anticancer drug with significant clinical activity

Ann Intern Med. 1974 Feb;80(2):249-59. doi: 10.7326/0003-4819-80-2-249.
No abstract available

Publication types

  • Review

MeSH terms

  • Adenocarcinoma / drug therapy
  • Animals
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / drug therapy
  • Carcinoma, Bronchogenic / drug therapy
  • Carcinoma, Squamous Cell / drug therapy
  • Chemical Phenomena
  • Chemistry
  • Doxorubicin / administration & dosage
  • Doxorubicin / therapeutic use*
  • Doxorubicin / toxicity
  • Drug Combinations
  • Drug Evaluation
  • Female
  • Gastrointestinal Neoplasms / drug therapy
  • Hodgkin Disease / drug therapy
  • Humans
  • Leukemia L1210 / drug therapy
  • Lung Neoplasms / drug therapy
  • Male
  • Melanoma / drug therapy
  • Mice
  • Multiple Myeloma / drug therapy
  • Neoplasms / drug therapy*
  • Neuroblastoma / drug therapy
  • Ovarian Neoplasms / drug therapy
  • Prostatic Neoplasms / drug therapy
  • Sarcoma / drug therapy
  • Stomatitis / chemically induced
  • Testicular Neoplasms / drug therapy
  • Thyroid Neoplasms / drug therapy
  • Urinary Bladder Neoplasms / drug therapy
  • Uterine Neoplasms / drug therapy

Substances

  • Antineoplastic Agents
  • Drug Combinations
  • Doxorubicin